通过恢复DUSP1依赖的线粒体质量控制,达帕格利弗洛辛维持了3型心脏病综合征中的心脏功能
Zunyan Li1,2, Ang Zhang2, Huida Lu2
1Department of Cardiology, Chengde Medical University, Chengde, 067000, China.
Acta diabetologica
|August 23, 2025
概括
通过双特异性酸酶1 (DUSP1) 实现线粒体质量控制 (MQC) 的正常化,抗糖尿病药物达帕格利弗洛辛 (DAPA) 改善了心脏功能. 这突出了DAPA作为CRS-3相关心脏功能障碍的潜在治疗方法.
科学领域:
- 心血管研究
- 线粒体生物学
- 药理学
背景情况:
- 3型心脏综合征 (CRS-3) 涉及由于损伤导致的心脏功能障碍.
- 通过双特异性酸酶1 (DUSP1) 调节的线粒体质量控制 (MQC) 对于维持心脏功能至关重要.
- 已知抗糖尿病药物达帕格利弗洛辛 (DAPA) 有和心脏保护作用.
研究的目的:
- 通过使MQC正常化,研究DAPA是否可以缓解CRS-3引起的心脏功能障碍.
- 研究DUSP1对CRS-3中DAPA对MQC和心脏功能的影响.
主要方法:
- 在小鼠中通过缺血/再输液诱导CRS-3.
- 通过测量心脏功能,心肌损伤生物标志物,氧化应激,炎症和亡来评估DAPA的影响.
- 在心肌细胞中进行了MQC测试 (线粒体动力学,线粒体,生物发生).
- 在对DAPA- DUSP1相互作用的对接分析中,使用了DUSP1淘汰的小鼠来评估DUSP1的作用.
主要成果:
- 根据剂量,DAPA改善了心脏功能和降低了CRS-3标志物.
- DAPA通过增强线粒体动力学,线粒体吸食和生物发生来稳定MQC.
- DAPA与DUSP1直接相互作用,抑制其核转移.
- 在DUSP1绝杀小鼠中,DAPA对MQC和心脏功能的有益作用被消除.
结论:
- 缺陷的MQC是CRS-3相关心脏功能障碍的一个关键因素.
- DAPA使DUSP1依赖的MQC正常化,为CRS-3心脏并发症提供治疗策略.
相关概念视频
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:23Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
01:11Renal Failure: Dose Adjustments
153
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
153
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
761
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
761